Serina Therapeutics’ CEO Selected as Panelist at 2014 Neurotech Investing and Partnering Conference

Huntsville, AL, April 21, 2014

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that Dr. Randall Moreadith, President and CEO, will be a panelist at the Neurotech Investing and Partnering Conference April 23-24 in Boston, Massachusetts.

“The Neurotech Partnering Conference is an exceptional meeting for companies with interest in partnering programs in neuroscience,” stated Dr. Moreadith. “It is a privilege to be selected as a panelist this year in the Parkinson’s and Movement Disorders session, where we will update the clinical and scientific community on progress made with SER-214.”

SER-214 is Serina’s most advanced polymer conjugate, with plans to enter a Phase I trial in patients later this year. It is a once-per-week injectable that results in continuous drug delivery, a long-sought clinical strategy to ameliorate the sometimes disabling consequences of oral treatment with short-acting L-DOPA formulations.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

About Neurotech Investor and Partnering Conference

The Neurotech Investor and Partnering Conference is one of the premier partnering and investing conferences for the neurotechnology industry, which includes sessions devoted to pharmaceuticals, medical devices and diagnostics. The conference will be held Wednesday and Thursday, April 23-24, 2014 at the Ritz-Carlton in Boston. The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. This conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics. Executives attending the conference will be updated on next generation treatments for Alzheimer’s, addiction, anxiety, depression, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, Parkinson’s and more.